Alerta

METHOD FOR PROVIDING INFORMATION FOR PREDICTING RISK GROUP FOR DEVELOPING ALZHEIMER'S DISEASE OR RISK GROUP FOR EARLY ONSET OF ALZHEIMER'S SYMPTOMS, OR RISK GROUP FOR DEVELOPING AMNESTIC MILD COGNITIVE IMPAIRMENT AND/OR PET-POSITIVE RISK GROUP FOR AMYLOID b DEPOSITION, BASED ON EUROPEAN POPULATION DATA

Resumen de: US2025277268A1

Embodiments of the present disclosure herein relate to a method for providing information for predicting a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and/or a positron emission tomography (PET)-positive risk group for amyloid β deposition, based on European population data. In an embodiment, the method makes it possible to accurately predict a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and/or a positron emission tomography (PET)-positive risk group for amyloid β deposition by using only at least 11 single-nucleotide polymorphisms, and the ability to predict the risk groups is further enhanced when up to and at most 39 additional single-nucleotide polymorphisms are used.

SKIN BIOMARKER

Resumen de: US2025277798A1

The invention relates to skin biomarkers, and in particular, to skin biomarkers for diagnosing and prognosing neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, as well as diagnostic and prognostic methods and kits for these conditions. The invention also provides methods of treating neurodegenerative disorders. The invention further provides the use of biomarkers in the skin for skin aging (biological & chronological), and kits for detecting and quantifying skin aging, and also methods for treating, preventing or slowing down skin aging.

PHOSPHO-TAU ANTIBODIES AND METHODS OF USE

Resumen de: US2025277799A1

Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.

METHODS OF TREATING A COGNITIVE IMPAIRMENT

Resumen de: WO2025181335A1

The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and/or low volume plasma exchange. Also provided are kits suitable for performing such methods.

GFAP DETECTION METHOD, METHOD FOR ASSISTING DIAGNOSIS OF ALZHEIMER 'S DISEASE, AND KIT USED THEREFOR

Resumen de: WO2025182761A1

Provided is a method for detecting GFAP in a sample by immunoassay, the method including a first step for forming a complex of a first antibody and GFAP, and a second step for forming a complex of a second antibody and GFAP, the first antibody binding to a region consisting of amino acids at positions 111 to 115 in the amino acid sequence of GFAP.

Omega-3 fatty acid, homocystein and vitamin D levels to identify and attenuate cognitive aging in individuals

Resumen de: AU2025220690A1

A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and 5 homocysteine, independently in one or more samples obtained from the subject. A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and 5 homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject. ug m e t h o d f o r i d e n t i f y i n g p r e - d i s p o s i t i o n t o c o g n i t i v e d e c l i n e i n a s u b j e c t , t h e m e t h o d u g c o m p r i s i n g d e t e r m i n i n g l e v e l s o f : ( a ) o m e g a - f a t t y a c i d s , a n d v i t a m i n o r a m e t a b o l i t e t h e r e o f ; ( b ) o m e g a - f a t t y a c i d s , a n d h o m o c y s t e i n e ; ( c ) v i t a m i n o r a m e t a b o l i t e t h e r e o f , a n d h o m o c y s t e i n e ; o r ( d ) o m e g a - f a t t y a c i d s , v i t a m i n o r a m e t a b o l i t e t h e r e o f , a n d h o m o c y s t e i n e , i n d e p e n d e n t l

靶向人TAU的化合物和方法

Resumen de: JP2024147610A

To provide antibodies for use in the treatment of neurodegenerative diseases, or pharmaceutical compositions thereof.SOLUTION: The present invention provides compounds and methods targeting human tau, particularly human tau phosphorylated at threonine (217) and isoforms of tau expressed only in the CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of neurodegenerative diseases such as AD, PSP and FTD.SELECTED DRAWING: None

An imaging biomarker that can diagnose Alzheimer's disease patients with symptoms of Lewy body disease by distinguishing them from normal controls

Resumen de: KR20250129282A

본 발명은 루이소체병의 증상을 동반한 알츠하이머병 환자를 정상대조군과 구분하여 진단할 수 있는 영상 바이오 마커에 관한 것으로, 보다 상세하게는, 본 발명은 중뇌 흑색질의 도파민 운반체 섭취율(DAT-SN), 및 선조체 조가비핵의 조기 도파민 섭취율 대 지연 도파민 섭취율의 비율(E/D-PP)을 영상 바이오마커로 사용하여 정상대조군과 구별하여 루이소체병의 증상을 동반한 알츠하이머병 환자의 진단 정확도를 높이는 효과를 제공한다.

Antibodies recognizing tau

Resumen de: NZ746574A

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

PROTEIN ANTIGEN COMBINATION CONTAINING SERF2 AND APPLICATION THEREOF

Resumen de: US2025271453A1

A protein antigen combination containing SERF2 and applications thereof in the field of biological detection are disclosed. The antigen combination for detecting autoantibodies can distinguish Alzheimer's disease (AD) from frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB), and the antigen combination at least includes protein fragments of SERF2. The new protein antigen composition can not only effectively identify patients with AD, but also effectively distinguish AD from FTD and DLB, enabling accurate identification of AD. It is of great importance in terms of diagnostic applications and research.

BIOMARKERS, COMPOSITIONS, KITS, AND METHODS DISTINGUISHING ACUTE GERIATRIC TBI FROM PRE-EXISTING DEMENTIA OR COGNITIVE IMPAIRMENT

Resumen de: WO2025179300A1

Methods, compositions, and kits are capable of detecting, identifying, diagnosing, prognosing, assessing, monitoring, and/or treating a neurological injury such as acute TBI and distinguishing geriatric TBI from conditions such as dementia, Alzheimer's Disease, Parkinson's disease and the like. Also disclosed are methods of testing elderly patients who have or are suspected of having traumatic brain injury using panels of biomarkers that distinguish TBI from dementia, and, optionally, treating such patients for TBI or dementia based upon the results of the biomarker tests.

TAU BINDING MOLECULES

Resumen de: US2025270301A1

The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to antibodies, specific for isolated recombinant peptides comprising an epitope from human tau 2N4R and to such antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.

COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES

Resumen de: US2025268982A1

Non-aggregating protein analogues of proteins involved in a proteinopathy, for example Alzheimer's disease, are provided. The protein has a beta-sheet aggregation domain, and the non-aggregating protein analogue has a beta-sheet destabilizing modification in the beta-sheet aggregation domain but substantially retains wild type protein function. The beta-sheet destabilizing modification can be a substitution of a naturally occurring amino acid for a non-naturally occurring amino acid. Methods of treating a proteinopathy using the non-aggregating protein analogues and methods of designing a non-aggregating protein analogue are provided.

METHODS FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE

Resumen de: US2025270618A1

Provided herein are methods for diagnosing and treating Alzheimer's disease in a subject comprising determining the expression level of three, four or five members of a panel of proteins in a biological sample obtained from the subject.

COMPOSITION FOR PREVENTING OR TREATING DETERIORATION IN BRAIN FUNCTION OR MAINTAINING OR IMPROVING BRAIN FUNCTION

Resumen de: US2025268952A1

The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.

IDENTIFYING A SUBJECT SUFFERING FROM ALZHEIMER'S DEMENTIA OR BEING AT RISK OF DEVELOPING ALZHEIMER'S DEMENTIA

Resumen de: CN119998661A

In a first aspect, the present invention relates to a method for identifying a subject suffering from or at risk of developing Alzheimer's dementia (AD), the method comprising: (a) determining in a first bodily fluid sample of the subject at least an amount of a compound having a mass of 110.0367 in grams/mole; (b) determining an amount of the same compound as in (a) in a second body fluid sample of the subject; (c) determining a change in the amount of the compound determined according to (a) compared to the corresponding amount of the compound determined according to (b); (d) analyzing the change determined in (c) using a computer-implemented prediction algorithm capable of predicting AD in the subject based on the compound, thereby identifying a subject having AD or at risk of developing Alzheimer's dementia if AD is predicted; wherein the first body fluid sample is obtained prior to administration of thietherazine or a pharmaceutically acceptable salt thereof, and the second body fluid sample is obtained after administration of thietherazine or a pharmaceutically acceptable salt thereof to the subject.

METHOD FOR DETECTING SOLUBLE OLIGOMERIC AMYLOID BETA

Resumen de: US2025262337A1

A method for detecting soluble oligomeric amyloid β in a subject is provided.

MICROGLIAL CELLS AS THERAPEUTIC TARGETS IN NEURODEVELOPMENTAL DISORDERS

Resumen de: US2025262247A1

The disclosure provides methods and compositions related to microglial cell development and therapies in neuronal development.

STEREOTYPIC BCR CLONOTYPES IN ALZHEIMER'S DISEASE PATIENTS AND USE THEREOF

Resumen de: US2025264482A1

The present specification discloses a composition, a system, and a method for predicting or diagnosing Alzheimer's disease, comprising a detecting agent of a B cell receptor clonotype specific to an Alzheimer's disease patient, and the composition according to one aspect of the present invention has an excellent effect in predicting or diagnosing Alzheimer's disease by simply using peripheral blood mononuclear cells isolated from a subject, in addition to methods such as MRI and PET scans using radioactive substances, by comprising a detecting agent of a B cell receptor (BCR) clonotype specific to an Alzheimer's disease patient.

ELECTRONIC APPARATUS AND METHOD FOR PREDICTING SLEEP EFFICIENCY IN OLDER ADULTS LIVING WITH DEMENTIA

Resumen de: KR20250124673A

본 발명에 따른 치매 노인의 수면 효율을 예측하는 전자 장치는 통신부; 메모리; 상기 통신부 및 상기 메모리와 연결된 적어도 하나의 프로세서를 포함하고, 상기 적어도 하나의 프로세서는, 사용자의 활동 데이터, 수면 데이터 및 생체 데이터를 획득하고, 상기 활동 데이터, 상기 수면 데이터 및 상기 생체 데이터를 입력으로 하여 치매 노인의 수면 효율을 예측하도록 학습된 수면 효율 예측 모델에 입력 파라미터를 입력하여 각 치매 노인의 수면 효율을 출력하도록 구성되며, 상기 생체 데이터는 상기 치매 노인의 신체에 장착된 땀패치를 탈착하여 소킹(soaking)한 후 추출된 싸이토카인의 종류 및 수치 정보를 포함할 수 있다.

強毒性アミロイド蛋白オリゴマーの診断における使用

Resumen de: CN119768689A

Use of a novel highly toxic amyloid oligomer A beta o * 3F as a target for diagnosis of early and mid-advanced Alzheimer's disease (AD) and AD-derived mild cognitive impairment (MCI), A beta o * 3F is specifically bound by a 3F antibody, and exists in cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and AD-derived MCI patients, the Abeta oligomers have the advantages that the Abeta oligomers are high-toxicity oligomers, the levels of the Abeta oligomers are remarkably different in CSF, blood and/or brain tissues of AD patients, MCI patients and healthy old people, and the Abeta oligomers are super-toxicity oligomers, are the most major toxic components in A beta oligomer mixtures, have strong pathogenic effects and play a key role in occurrence and development of AD.

Perfiles de tau fosforilada y beta amiloide en csf como biomarcadores de tauopatías

Resumen de: MX2023011495A

The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues and optionally Ab species to diagnose a subject, guide treatment decisions, and select subjects for clinical trials.

MODIFIED POLYPEPTIDE AND USE THEREOF

Resumen de: WO2025166920A1

The present invention belongs to the technical field of detection reagents, and relates to a modified polypeptide and the use thereof. The modified β amyloid protein polypeptide comprises peptide fragment I, peptide fragment II, and peptide fragment III located between the peptide fragment I and the peptide fragment II. The peptide fragment I contains a sequence as shown in SEQ ID NO: 9, the peptide fragment II contains a sequence as shown in SEQ ID NO: 18, and the peptide fragment III is composed of non-hydrophobic amino acids. Linker compounds are added between the peptide fragment I and the peptide fragment III, as well as between the peptide fragment II and the peptide fragment III. Compared with the original polypeptide, the modified polypeptide is reduced in terms of synthesis difficulty and cost, and improved in terms of stability. In terms of reaction activity with antibodies, the modified form is consistent with the original polypeptide, is a better raw material form for a calibrator of a diagnostic reagent, and is beneficial to development and wide application of a detection kit.

ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF

Resumen de: US2025257124A1

The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

METHOD AND COMPOSITION FOR GENERATING BASAL FOREBRAIN CHOLINERGIC NEURONS (BFCNS)

Nº publicación: US2025257318A1 14/08/2025

Solicitante:

NEW YORK STEM CELL FOUND INC [US]
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US]
New York Stem Cell Foundation, Inc,
Icahn School of Medicine at Mount Sinai

Resumen de: US2025257318A1

The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.